Investigating the effect of oral supplementation containing jujube and saffron on recovery and controlling the symptoms of patients with covid-19

Investigating the effect of oral supplementation containing jujube and saffron on recovery and controlling the symptoms of patients with covid-19

A clinical trial with control group, parallel groups, double-blind, randomized, phase 2-3 on 60 patients. Random allocation software has used for randomization.

Valiasr Hospital, Birjand; After obtaining informed written consent, patients will be randomly divided into 2 groups (placebo and supplement). A standard treatment will be provided for both. The duration of the intervention is 2 weeks and the received dose is equal to 15 ml of the supplement three times a day after each meal orally. Tests and examinations of patients will be performed daily. During the study, with the exception of the pharmacist (who has no role in the clinical study and evaluations), the rest of the project partners, including infectious disease specialists, radiologists, nurses, and project analysts, will not know how the drug and placebo are allocated.

Inclusion criteria: Clinical or paraclinical confirmation of Covid-19; Absence of underlying disease including diabetes, thyroid disorders, cardiovascular, autoimmune, hemorrhagic, and other lung diseases; No pregnancy and lactation. Exclusion criteria: Patients with a severe form of Corona disease (patients under ventilator, patients with oxygen saturation percentage below 88 mm Hg, and patients admitted to the ICU), Patient's unwillingness to continue the project; Sensitivity to the components of supplement.

Intervention group includes patients with Corona who receive supplements containing jujube and saffron. Comparison group includes patients with Corona who receive placebo intervention.

radiological changes, duration of hospitalization, body temperature, cough rate, CBC indices

Randomized double-blind controlled clinical trial randomization using random allocation software According to the randomization, each supplement or placebo sample is assigned a number and the patient will not be informed about taking the drug or placebo (Numbers from 1 to 60).

Patients will be notified to participate in the study and obtaining a consent form but they will be blind to the supplements or placebo. During the study, with the exception of the pharmacist (who has no role in the clinical study and evaluations), the rest of the project partners, including infectious disease specialists, radiologists, nurses, and project analysts, will not know how the drug and placebo are allocated. Supplement and placebo are also identical in appearance so that they are not recognizable to patients.